BMI for Mounjaro on the NHS: Understanding the Thresholds That Decide Eligibility

The decision you're actually facing: NHS route, private route, or wait?

Most people searching this question are not simply curious about policy. They have a BMI in mind, perhaps a few health conditions, and they want to know honestly whether the NHS door is open to them right now, or whether they'll be waiting years. That's a practical decision, and it deserves a straight answer.

At present, NHS access to Mounjaro follows a phased schedule set by NHS England. The first cohort (adults with a BMI of 40 or above plus four or more of the five qualifying conditions) opened in June 2025. A second cohort covering BMI 35–39.9 with the same four-condition requirement became active in June 2026. A third cohort (BMI 40-plus with three conditions) is expected around March 2027. Each phase is conditional: meeting the BMI threshold and the condition count is necessary, but GPs also need to have opted in to the new prescribing contract, and patients must engage with wraparound diet and lifestyle support. Ticking the numerical boxes does not guarantee a prescription the following week.

If your BMI sits below 35, or you have fewer than four of the listed conditions, you are not in any current NHS cohort. That's where the private route becomes relevant, and it's worth understanding both paths clearly before deciding. The full picture of Mounjaro on the NHS covers the cohort timeline in more detail.

The five qualifying conditions and what the NHS BMI number actually requires

NICE's TA1026 specifies five conditions that count toward the qualifying threshold: high blood pressure, dyslipidaemia (raised cholesterol or triglycerides), obstructive sleep apnoea, cardiovascular disease, and type 2 diabetes. You need four of those five alongside your BMI figure to enter the current NHS cohorts. It's a deliberately high bar, higher than the clinical licence, which simply requires a BMI of 30 or above, or 27 with a weight-related condition.

For people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, the BMI thresholds drop by 2.5 kg/m² at every stage. So the current 35 threshold becomes 32.5 for those groups, and the forthcoming 40-plus cohort becomes 37.5. This adjustment reflects established evidence that health risks linked to excess weight occur at lower BMI values in these populations.

One practical note from NHS England's guidance on weight-management injections: even patients who meet every criterion must participate in a structured support programme covering diet, physical activity and behaviour change. The medicine does not come as a standalone prescription; it comes as part of a managed package.

If you want to check your own numbers against the current eligibility criteria, the detailed NHS eligibility breakdown sets out each cohort with its exact BMI and condition requirements.

What the BMI threshold looks like for private prescriptions

The licensed eligibility for Mounjaro is considerably broader than what the NHS currently funds. The medicine is licensed for adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related health condition. A private prescriber assessing you for tirzepatide works from those licensed criteria, not from the NHS cohort rules.

That said, a lower BMI does not mean automatic approval. A private prescription still requires a full clinical assessment by a registered prescriber who looks at your overall health picture: medications you take, relevant conditions, any contraindications. The number on a BMI calculator is the starting point, not the finish line. For a closer look at how the licensed thresholds compare to the NHS ones, the private BMI requirements for Mounjaro page sets those out directly.

At nume, sorry, at nume, every consultation is read by a GPhC-registered Independent Prescriber on the same day you complete it. There is no algorithm making the call. If you're considering the private route, what happens if your BMI is on the lower end is worth reading before you start.

Cost, availability, and where to go next

NHS prescriptions for Mounjaro carry the standard prescription charge (or are free if you hold an exemption). Private prescriptions are priced differently, and the cost of private tirzepatide has shifted considerably since Eli Lilly adjusted its UK list price in September 2025, typical private prices now range roughly £149 to £375 per month depending on dose and provider, as widely reported at the time. A legitimate private price always includes the clinical assessment and prescription; any listing that separates those out, or offers a dramatically lower figure, deserves scrutiny.

For context on what private treatment actually includes and what the price covers, the buying Mounjaro privately page explains the full process. If you're weighing up whether to wait for NHS access or proceed privately, the Mounjaro overview sets out the clinical picture, the SURMOUNT-1 trial reported an average weight reduction of around 20–21% at the highest dose over 72 weeks, figures NICE cited when making its recommendation.

When treatment does arrive (by private prescription, dispatched the same day and delivered by DPD the next working day in plain packaging) the pen itself is a pre-filled KwikPen, refrigerated until use, each one containing four weekly doses. Starting at 2.5mg, titration is managed by your prescriber, not by guesswork.

If you'd like a clinical team to review your situation properly, you can check your eligibility with our prescribers, no commitment, no cost, just a genuine assessment.